Beam Therapeutics, Inc.Find Ratings Reports
BEAM THERAPEUTICS INC's gross profit margin for the third quarter of its fiscal year 2021 has significantly decreased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the subsector when comparing revenue growth, but not when comparing net income growth.
At the same time, stockholders' equity ("net worth") has greatly increased by 326.75% from the same quarter last year.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY21||Q3 FY20|
|Net Sales ($mil)||0.76||0.01|
|Net Income ($mil)||-28.12||-34.45|
|Balance Sheet||Q3 FY21||Q3 FY20|
|Cash & Equiv. ($mil)||933.41||202.22|
|Total Assets ($mil)||1156.56||278.27|
|Total Debt ($mil)||0.0||34.33|
|Profitability||Q3 FY21||Q3 FY20|
|Gross Profit Margin||-9126.34||100.0|
|Return on Assets||-34.7||-45.63|
|Return on Equity||-47.01||-63.47|
|Debt||Q3 FY21||Q3 FY20|
|Share Data||Q3 FY21||Q3 FY20|
|Shares outstanding (mil)||64.45||50.44|
|Div / share||0.0||0.0|
|Book value / share||13.25||3.97|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||588287.0||802515.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 6.77 indicates a significant premium versus the S&P 500 average of 4.74 and a significant discount versus the subsector average of 10.99. The price-to-sales ratio is well above both the S&P 500 average and the subsector average, indicating a premium. The valuation analysis reveals that, BEAM THERAPEUTICS INC seems to be trading at a premium to investment alternatives.
|BEAM NM||Peers 35.44||BEAM NA||Peers 21.78|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
BEAM's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures.
Ratio not available.
|BEAM NM||Peers 19.02||BEAM NA||Peers 1.05|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
BEAM's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|BEAM 6.77||Peers 10.99||BEAM -154.37||Peers 55.21|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
BEAM is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, BEAM is expected to significantly trail its peers on the basis of its earnings growth rate.
|BEAM 7411.27||Peers 78.20||BEAM 3154.16||Peers 500.96|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
BEAM is trading at a significant premium to its subsector.
Higher. A sales growth rate that exceeds the subsector implies that a company is gaining market share.
BEAM has a sales growth rate that significantly exceeds its peers.